Sitostanol是常见植物甾醇sitosterol的一种代谢物，能降低胆固醇的胶束溶解度。
Cas No.:83-45-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sitostanol is a metabolite of the common plant sterol sitosterol that can decrease micellar solubility of cholesterol [1]. Sitostanol can reduce intestinal absorption of cholesterol and positively affect cholesterol metabolism in intestinal epithelial cells [2]. Sitostanol can be used as a model compound to develop GC-MS methods for characterizing and quantifying the oxidation products of Sitostanol [3].
In vitro, Sitostanol (1.2µM) treatment of peripheral blood mononuclear cells (PBMCs) from asthma patients for 48 hours increased the number of Treg cells and promoted the secretion of IL-17 and IL-10[4]. Treatment with Sitostanol (1.2µM) for 24h significantly reduced maximal respiration in hepG2 cells at low glucose concentrations[5].
In vivo, Sitostanol treatment via oral administration at a dose of 0.64g/day for 10 weeks significantly reduced plasma cholesterol levels and inhibited the development of atherosclerosis in rabbits[6]. Daily oral administration of Sitostanol (2.25g/100g) for 4 weeks significantly reduced plasma low-density lipoprotein cholesterol (LDL-C) concentrations and altered hepatic cholesterol metabolism in guinea pigs[7].
References:
[1] Ikeda I, Tanabe Y, Sugano M. Effects of sitosterol and sitostanol on micellar solubility of cholesterol[J]. Journal of nutritional science and vitaminology, 1989, 35(4): 361-369.
[2] Plat J, Mensink R P. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects[J]. The American journal of cardiology, 2005, 96(1): 15-22.
[3] Soupas L, Juntunen L, Säynäjoki S, et al. GC‐MS method for characterization and quantification of sitostanol oxidation products[J]. Journal of the American Oil Chemists' Society, 2004, 81(2): 135-141.
[4] Brüll F, Mensink R P, Steinbusch M F, et al. Beneficial effects of sitostanol on the attenuated immune function in asthma patients: results of an in vitro approach[J]. 2012.
[5] Nascimento E B M, Konings M, Schaart G, et al. In vitro effects of sitosterol and sitostanol on mitochondrial respiration in human brown adipocytes, myotubes and hepatocytes[J]. European journal of nutrition, 2020, 59(5): 2039-2045.
[6] Ntanios F Y, Jones P J H, Frohlich J J. Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl transferase activity in rabbits[J]. Atherosclerosis, 1998, 138(1): 101-110.
[7] Ramjiganesh T, Roy S, McIntyre J C, et al. The hypocholesterolaemic effects of sitostanol in the guinea pig are in part related to changes in hepatic lipids and lipoprotein composition[J]. British journal of nutrition, 2001, 85(2): 165-172.
Sitostanol是常见植物甾醇sitosterol的一种代谢物，能降低胆固醇的胶束溶解度[1]。Sitostanol可减少肠道对胆固醇的吸收，并对肠上皮细胞的胆固醇代谢产生积极影响[2]。Sitostanol可作为模型化合物，用于开发GC-MS方法以表征和定量Sitostanol的氧化产物[3]。
在体外，使用1.2µM的Sitostanol处理哮喘患者的外周血单个核细胞（PBMCs）48小时，增加了调节性T细胞（Treg）的数量，并促进了IL-17和IL-10的分泌[4]。使用1.2µM的Sitostanol处理24小时，显著降低了低葡萄糖浓度下hepG2细胞的最大呼吸能力[5]。
在体内，每日口服给予0.64g剂量的Sitostanol，持续10周，显著降低了兔子的血浆胆固醇水平，并抑制了动脉粥样硬化的发展[6]。每日口服给予Sitostanol（2.25g/100g），持续4周，显著降低了豚鼠的血浆低密度脂蛋白胆固醇（LDL-C）浓度，并改变了其肝脏胆固醇代谢[7]。
| Cell experiment [1]: | |
Cell lines | Peripheral blood mononuclear cells (PBMCs) |
Preparation Method | PBMCs were cultured in RPMI 1640, containing 25mM HEPES and L-glutamine, supplemented with 1% penicillin/streptomycin, 1% sodium pyruvate, and 1% human serum pool, heat-inactivated for 30 minutes at 56°C. PBMCs were seeded 1×106/ml in 24-wells flat bottom culture plates. Cells were then incubated with 1.2µM Sitostanol for 48h for cytokine assays. |
Reaction Conditions | 1.2µM; 48h |
Applications | Sitostanol treatment enhanced the levels of IL-10 and IL-17 in PBMCs. |
| Animal experiment [2]: | |
Animal models | Male Hartley guinea pigs |
Preparation Method | Fifty male Hartley guinea pigs, weighing between 300 and 400g, were randomly assigned to one of the 2 dietary groups (ten per group). One group received Sitostanol 2.5g/100g/day. The control group fed a low-cholesterol diet. Two guinea pigs were kept per metal cage and were housed in a light cycle room (light from 07:00 to 19:00) with a temperature of 23℃ for a period of 4 weeks. The guinea pigs had free access to diet and water. Animals were killed by cardiac puncture after halothane anaesthesia, and blood was collected to analyze plasma lipoproteins for characterization. Liver was harvested to determine hepatic lipids. |
Dosage form | 2.5g/100g/day for 4 weeks; p.o. |
Applications | Sitostanol treatment significantly reduced plasma LDL-C concentrations and altered hepatic cholesterol metabolism in guinea pigs. |
References: | |
| Cas No. | 83-45-4 | SDF | |
| 别名 | 豆甾烷醇 | ||
| 化学名 | (5α)-stigmastan-3β-ol | ||
| Canonical SMILES | CC(C)[C@H](CC)CC[C@@H](C)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| 分子式 | C29H52O | 分子量 | 416.7 |
| 溶解度 | Ethanol : 5 mg/mL (12.00 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3998 mL | 11.999 mL | 23.9981 mL |
| 5 mM | 480 μL | 2.3998 mL | 4.7996 mL |
| 10 mM | 240 μL | 1.1999 mL | 2.3998 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet